Arbidol treatment with reduced mortality of adult patients with COVID-19 in Wuhan, China: a retrospective cohort study

Qibin Liu[1*], Xuemin Fang[2*], Lu Tian[3*], Naveen Vankadari[4], Xianxiang Chen[5], Ke Wang[6], Dan Li[7], Xiyong Dai[8], Feng Xu[9], Lei Shen[10], Bing Wang[11], Li Yao[12], Peng Peng[13#]

[1] Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China; Liuqibin0221@163.com

[2] Graduate School of Health Innovation, Kanagawa University of Human Services, 2F Bldg.2-A, 3-25-10, Tonomachi Kawasaki-ku, Kawasaki City, Kanagawa 210-0821, Japan, m.fanfg-ft5@kuhs.ac.jp

[3] Department of Biomedical Data Science, Stanford University, CA 94305, USA, lutian@stanford.edu

[4] Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Victoria 3800, Australia. Naveen.vankadari@monash.edu

[5] Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China; 2272534937@qq.com

[6] Department of Pulmonary and Critical Care Medicine, Tongji Hospital, Huazhong University of Science and Technology, 1095 Jiefang Avenue, 430030, Wuhan City, Hubei Province, China, Chinawangke13409@163.com

[7] Department of Pediatric Surgery, Union Hospital, Huazhong University of Science and Technology, 1277 Jiefang Avenue, 430022, Wuhan City, Hubei Province, China, D201478239@alumni.hust.edu.cn

[8] Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China, daixiyong71@126.com

[9] Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China, victor_fsxq@163.com

[10] Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China, shen0811@aliyun.com

[11] Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China, 779238021@qq.com

[12] Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China, 354608920@qq.com

[13] Wuhan Pulmonary Hospital, Director, Wuhan Institute for Tuberculosis Control, No. 28 Baofeng Road, Qiaokou District, Wuhan City, Hubei Province, China, pengpengwg@126.com

*Authors contributed equally
#Correspondence: pengpengwg@126.com (Tel.:+86-027-83605535)

BACKGROUND

The worldwide COVID-19 pandemic is increasing exponentially and demands an effective and promising therapy at most emergency.

METHODS

We have assembled a cohort consisting 504 hospitalized COVID-19 patients. Detailed information on patients' characteristics and antiviral medication use during their stay at designated hospitals along with their pre and post treatment results were collected.

The study objective is to evaluate the treatment efficacy of Arbidol, together with the concurrent drugs Oseltamivir and Lopinavir/Ritonavir on mortality and lesion absorption based on chest CT scan.

FINDINGS

The overall mortality rate was 15.67% in the cohort. The older age, lower SpO2 level, larger lesion, early admission date, and the presence of pre-existing conditions were associated with higher mortality. After adjusting for the patients age, sex, pre-existing condition, SpO2, lesion size, admission date, hospital, and concurrent antiviral drug use, Arbidol was found promising and associated with reduced mortality. The OR for Arbidol is 0·183 (95% CI, 0·075 to 0·446; P<0·001). Furthermore, Arbidol is also associated with faster lesion absorption after adjusting for patient's characteristics and concurrent antiviral drug use (P=0·0203).

INTERPRETATION

The broad-spectrum antiviral drug Arbidol was found to be associated with faster

4 Introduction

Since the first discovery of novel coronavirus disease 2019 (COVID-19) in Wuhan (China) in

December 2019,[1] more than 4.8 million people were infected and over 323,000 have died

across the globe as of May 22, 2020,[2,3] The world-wide rapid spread of the infection with

limited therapeutic options is leading to a global health emergency. Meanwhile scientists and

researchers are racing with time testing a huge variety of new and existing treatments. As of

April 8, 2020, there were 388 ongoing studies on COVID-19 that are recorded in the U.S.

National Library of Medicine of the NIH,[4] including studies involving plasma, stem cells, and

antiviral drugs, etc. For example, Liu et al (2020) presented preliminary results for 39 patients

suggesting a potential benefit of convalescent plasma treatment in reducing mortality.[5]

Much attention has been drawn to a few promising candidates, namely Remdesivir,

Lopinavir/Ritonavir, Hydroxychloroquine, Favipiravir and Umifenovir (Arbidol), however

most completed studies so far had negative results. Mehra et al (2020) reported a

multinational registry analysis of 96,032 patients and showed the use of Hydroxychloroquine

or Chloroquine was associated with decreased in-hospital survival and increased ventricular

arrhythmias;[6] Geleris et al (2020) also reported the result of an observational study of 1446

patients showing Hydroxychloroquine was not associated with significant benefit on a

composite endpoint of intubation or death;[7] Cao et al (2020) reported that no benefit was

observed with Lopinavir/Ritonavir treatment beyond standard care in a randomized,

controlled, open-label trial with 199 patients.[8] Chen et al (2020) reported a randomized

clinical trial of 240 patients comparing Favipiravir with Arbidol, and found that Favipiravir

did not significantly improve the clinical recovery rate at Day 7 as compared to Arbidol.[9]

Remdesivir has been regarded as one of the most promising drug candidates, with a total of

three trial results becoming available so far.[10-12] It was found to be superior to placebo in

shortening the time to recovery, but its effect on the mortality was not statistically

significant.[11] We are still nowhere close to finding the best cure.

In the search for effective COVID-19 therapies, most researchers are targeting ACE2 and

RdRp, but recent findings also suggest CD26 (DPP4) as another possible target.[13,14] Viral

entry is mediated via several pathways and it may not solely depend on the ACE2 which

warrants testing other host targets. Recently, Vankadari (2020) reported the binding and

mechanism of Arbidol action over the SARS-CoV-2 spike protein, which raises the

significance of Arbidol being a possible drug candidate for COVID-19 infection.[15]

In this study, we aim to evaluate the clinical effect of Arbidol with a retrospective cohort of

COVID-19 patients from Wuhan. We have also conducted molecular dynamics and time

course simulation studies in order to understand the mechanism of the Arbidol drug action

over the SARS-CoV-2 viral proteins.

Methods

Study design and participants

We have assembled a cohort consisting 504 in-patients with COVID-19 from three hospitals

in Wuhan: Wuhan Pulmonary Hospital (WPH), Tongji Hospital, and Union Hospital. All three

were designated COVID-19 hospitals during the outbreak. The study protocols were reviewed

and approved by the Ethics committee of WPH (WPE 2020-12). Patient records and

information were de-identified prior to the analysis.

Figure 1 shows the diagram of cohort design and patient selection. For WPH, we started with

all COVID-19 patients admitted between December 13, 2019 and March 21, 2020 and

excluded patients with ambiguous diagnosis as well as those with a primary cause of death

unrelated to COVID-19. After further excluding 119 patients who remained being

hospitalized by March 29, 2020, 373 patients from WPH were included. For Tongji Hospital,

100 COVID-19 patients admitted into two randomly selected hospital wards between

February 1, 2020 and February 5, 2002 were included. Similarly, for Union Hospital, 31

COVID-19 patients admitted into a randomly selected ward between January 26, 2002 and

February 24, 2002 were included. All patients in the study cohort have definitive outcomes,

i.e., discharged or deceased. All COVID-19 infections are confirmed by Real-Time PCR

(virus nucleic acid test).

Patients characteristics, medication and endpoints

We collected data on patients' clinical outcomes (death or discharge) as well as basic

characteristics, including age, sex, pre-existing conditions, SpO2 level at hospital admission,

use of oxygen and ventilators during the hospital stay, and patient's pre and post treatment

lung CT scan images.

The drug treatment options used in all three hospitals followed the Chinese National Health

Commission's evolving guideline for the treatment of COVID-19, "New Corona Virus

Pneumonia Diagnosis and Treatment Program". The majority of the patients received

Lopinavir/Ritonavir, Arbidol and Oseltamivir. With the development of the epidemic and the

guideline updates, Hydroxychloroquine and Favipiravir were also used to a small number of

patients. The prescription of antiviral medications and their administration time for each

patient were extracted from electronic medical records with written consents from the

clinicians. In this study, we specifically focus on three anti-viral medications, Arbidol,

Oseltamivir, and Lopinavir/Ritonavir.

The primary endpoint is in-hospital death, with date of death extracted from the medical

records. The secondary endpoint is the change in lesion size as measured by CT scans pre and

post the antiviral treatment. CT scan images were read by certified thoracic radiologists at the

respective hospitals to determine lesion size. The pre-treatment image was selected as the first

CT image after the patient's admission but before the initiation of the regular full-course

antiviral treatment. The post-treatment image was selected as the last CT scan taken before

patient's death or discharge, which is normally after completing the antiviral therapy cycle. To

ensure the comparability of the two CT images, we identified the plane with the largest lesion

in the pre-treatment CT scan, and used the same plane in the post-treatment CT scan. The

lesion in the selected plane was circled and size measured by the ImageJ software (Figure 2).[16]

Statistical analysis

Continuous and dichotomous patient characteristics were summarized by their mean (standard

deviation (SD)), and count (proportion), respectively. We compared the mortality rate

between patients who received Arbidol, or Oseltamivir, or Lopinavir/Ritonavir and those who

did not using Fisher's exact test. We then employed the logistic regression to estimate the

odds ratio (OR) associated with the treatment after adjusting sex, pre-existing condition,

medication use, hospital, and log-transformed age, SpO2 level, admission date and the lesion

size from the pre-treatment CT scan. Missing covariates were imputed by the medians of the

observed values. We also repeated the logistic regression for patients in WPH only, where the

potential sampling bias was the lowest. In addition, we performed Cox regression analyses

with time dependent covariates, setting value to 0 and 1 before and after the medication

prescription, respectively, to account for the timing of medication use.[17] We also conducted

linear regression analyses with the log-transformed ratio of lesion area absorption pre and

post the antiviral treatments. A small value of one was added to all lesions sizes to avoid log-

transformation of zero. The two-sided statistical significance level was set at 0.05. All

statistical analyses were conducted using the R 3.3.1 software.

Arbidol binding analysis

Docking studies with Arbidol and its binding analysis to SARS-CoV-2 spike glycoprotein was

performed as described in Vankadari (2020).[15] In brief, SwissDock

(http://swissdock.ch/docking) server was used to dock the Arbidol into the published structure

of SARS-CoV-2 spike glycoprotein trimer (PDB: 6VSB). Structural refinement was

completed using Coot (www.mrc-imb.cam.uk/) to ensure no clashes in the side chain

residues. Best dock score and highest binding free energies were taken into consideration to

select the best-possible docking site and mode of interaction. Arbidol binding interface and

the key residues interaction map was generated using the Maestro program. The molecular

dynamics with time course simulation studies were performed using DynOmics server (www.

http://gnm.csb.pitt.edu/). The final model with Arbidol docked in the homotrimer structure of

SARS-CoV-2 spike protein and all other structural figures were visualized using PyMol.

Role of the funding source

The authors report no funding.

Results

Cohort baseline characteristics

The cohort consists of 504 patients with confirmed COVID-19 infection from three hospitals:

373 patients from WPH, 100 patients from the Tongji Hospital, and 31 patients from the

Union hospital. Table 1 summarizes main drug treatment options administrated during

patient's stay at the respective hospital. 257 patients received Arbidol (51·0%); 66 patients

received Oseltamivir (13·1%); and 259 patients received Lopinavir/Ritonavir (51·4%). The

majority of the patients received two or more different treatments during their hospitalization.

Among the 504 patients, 245 (48·6%) were female, and 262 (52·0%) had pre-existing

conditions. The average age of the cohort was 59·5 (SD, 14·9) years old. The average Oxygen

level (SpO2) at admission was 92·8% (9·3%). Patients who received Arbidol had slightly

higher SpO2 level and smaller lesion area compared to other patients. Patients who received

Oseltamivir were younger. In contrast, patients who received Lopinavir/Ritonavir had more

pre-existing conditions. Patients admitted to the hospital early were more likely to receive

Oseltamivir and Lopinavir/Ritonavir. Table 2 summarizes the baseline patients characteristics

by hospital.

The association between the treatments and mortality

For the cohort of 504 patients, the overall mortality rate was 15·67%. The mortality rate was

9·39% among females, 21·62% among males. The mortality rate was 20·23% among patients

with pre-existing conditions, and 10·74% among patients without pre-existing conditions. The

mortality rate was 17·96% in WPH, 12·00% in Tongji Hospital, and 0% in Union hospital. In

this cohort, older age, lower SpO2 level at admission, larger lesion, and early admission date

were associated with higher mortality.

The mortality rate was 7·00% among patients who received Arbidol compared to 24·70%

among patients who did not. The odds ratio (OR) was 0·230 (95% confidence interval (CI),

0·124 to 0·411) favoring Arbidol. On the other hand, the mortality rate was 12·12% among

patients who received Oseltamivir, compared to 16·21% among patients who did not. The OR

was 0·713 (95% CI, 0·282 to 1·589) favoring Oseltamivir. The mortality rate was 14·29%

among patients who received Lopinavir/Ritonavir, compared to 17·14% among patients who

did not. The OR was 0·806 (95% CI, 0·483 to 1·341) favoring Lopinavir/Ritonavir. After

adjusting for sex, pre-existing conditions, log(age), log(SpO2), log(lesion size), log(admission

date) and hospital (model 1) using a multivariate logistic regression model, the OR was 0·169

(95% CI, 0·071 to 0·398) for Arbidol, 0·212 (95% CI, 0·072 to 0·623) for Oseltamivir, and

0·363 (95% CI, 0·165 to 0·795) for Lopinavir/Ritonavir. After further adjustment of

concurrent antiviral medications (model 2), the beneficial effect of Arbidol and Oseltamivir

have remained statistically significant: the adjusted OR was 0·183 (95% CI, 0·075 to 0·446;

p<0·001) for Arbidol and 0·220 (95% CI, 0·069 to 0·707; P=0·011) for Oseltamivir (Figure

3A).

The association between the treatments and the reduction of lung lesion sizes

There were 326 survivors with two available CT scans. The average reductions in lesion size

were 46·43% (SD: 29·00%) among the 209 patients who received Arbidol and 36·80% (SD:

24·95%) among the 117 patients who did not. The average reduction among the 55 patients

who received Oseltamivir was less than that among the 271 patients who did not (41·18% vs

43·34%). The reduction among the 186 patients who received Lopinavir/Ritonavir was also

less than the 140 patients who did not (37·26% vs. 50·56%). After adjusting for patients'

characteristics and concurrent antiviral drug use using a multivariate linear regression model,

the ratio of the lesion size (post-treatment to pre-treatment) among patients who received

Arbidol was 85·20% (95% CI, 74·47% to 97·48%; P=0·0203) of that among patients who did

not, suggesting a faster lesion absorption. Figure 3B summarized the linear regression

analysis results for all three antiviral drugs. Figure 4A shows the boxplots of the lesion

absorptions in the stratified subgroups of patients by the three antiviral drugs, with patients

who received Arbidol (dark turquoise) showing more absorption than patients who did not

(light turquoise).

Subgroup analysis in WPH

For the 373 patients in WPH, the mortality rate was 7·09% among patients who received

Arbidol vs. 24·57% among patients who did not (OR=0·234, 95% CI, 0·103 to 0·481,

P<0·001). After adjusting for sex, pre-existing condition, log(age), log(SpO2), log(lesion

area), log(admission date), and concurrent antiviral drug use using a multivariate logistic

regression model, Arbidol was associated with significantly reduced mortality (OR, 0·193;

95% CI, 0·071 to 0·520, P=0·001). The effect of Oseltamivir was marginally significant (OR,

0·326; 95% CI, 0·090 to 1·177; P=0·087). Figure 3C summarized detailed results.

Survival analysis

Among the patients who received Arbidol, the median prescription time was 1·50 (IQR: 0·50-

2·50, range, 0·50-31·50) days after admission. For Oseltamivir and Lopinavir/Ritonavir, the

median prescription time was 0·50 (IQR: 0·50 to 1·50, range, 0·50-25·50) and 0·50 (IQR:

0·50 to 2·50, range, 0·50-32·50) days after admission, respectively. After adjusting for

baseline characteristics and concurrent antiviral drug use using a multivariate cox

proportional hazard ratio model, the hazard ratio was 0·350 (95% CI, 0·177 to 0·689;

P=0·002) for Arbidol, 0·571 (95% CI, 0·269 to 1·211) for Oseltamivir, and 0·720 (95% CI,

0·426 to 1·218) for Lopinavir/Ritonavir based on Cox regression stratified by hospitals

(Figure 3D). Figure 4B shows the cumulative mortality curves for the three antiviral drugs.

There is a significant difference between the mortality curve for patients who received

Arbidol versus patients who did not (P < 0·001) whereas the differences are not statistically

significant for Oseltamivir (P = 0·34) and Lopinavir/Ritonavir (P = 0·33).

Arbidol and SARS-CoV-2 spike glycoprotein interaction

It is evident from the previous studies that Arbidol is potentially effective against SARS-

CoV-2.[13] The recent structural studies of Arbidol in complex with SARS-CoV-2 spike

glycoprotein underlines its role in impeding trimerization,[15] which is essential for virulence.

Here we address how this drug disrupts the viral spike glycoprotein through comprehensive

drug interaction via molecular dynamics and time course simulation studies. As shown in

Figure 5A, each monomer of spike glycoprotein consists of large surface for drug interaction

and it could completely accommodate the drug in the trimer interface (Figure 5A and 5B).

The time course simulation and drug interaction studies show that the Arbidol disrupt the

interface in all directions and its binding affinity found to be very high (Figure 5C). The

interaction is not only mediated by hydrogen bonding and van-der Wall forces but also by

several polar residues bridge with the spike glycoproteins (Figure 5D). Furthermore, the

dynamic simulation and domain movement or oscillation studies show that binding of Arbidol

to the spike glycoprotein increases the B-factor (stability factor) (Figure 5E), suggesting

protein is under higher movement and is less stable or tend to dissociate from other

monomers. These structural and molecular dynamic studies further corroborate our clinical

finding of CT scans showing greater viral clearance observed with Arbidol treatment.

Discussion

The study showed promising treatment effect of Arbidol on mortality and lesion absorption.

On the other hand, the benefit of Lopinavir/Ritonavir is inconclusive, which is consistent with

the previous finding of Cao et al. (2020), where Lopinavir/Ritonavir has reduced the mortality

from 25·0% to 19·2% in a randomized clinical trial, but failed to reach the statistical

significance threshold.[8] Recently, Xu et al, (2020) reported that the virologic conversion rate

in 49 patients who received Arbidol was significantly higher than that in 62 patients who
received the standard care (59·2% vs 40·3%, P=0.048).[19] In this study, the patients who
received Arbidol also had faster lung lesion absorption (55·1% vs 32·2%). Despite the limited
sample size, their results further corroborated our findings. The dual role of Arbidol in
inhibiting the fusion between the viral envelope and target host cell membrane as well as anti-
inflammation could be responsible for its observed efficacy.[20, 21]
Oseltamivir is normally prescribed for the treatment of influenza and has no known effect on
COVID-19 patients. However, some patients have been infected by both COVID-19 and
Influenza,[22] which may exacerbate their clinical conditions. It is very likely that a
combination of drugs or therapy including Oseltamivir can help this subgroup of patients due
to the effectiveness of Oseltamivir in treating severe illness caused by Influenza. In addition,
SARS-CoV-2 and influenza viruses share a similar region of viral spike protein, which may
also explain the potential effect of Oseltamivir in treating COVID-19 patients.[13]
There are some important limitations in the current study. First, the study is not a randomized
clinical trial, and therefore the observed treatment benefit of Arbidol and Oseltamivir may be
due to confounding effect. The analysis has adjusted for several known confounders including
age, comorbidities, admission date, and disease severity measured through SpO2 and CT
scan. Furthermore, given the size of the estimated treatment effect, the unmeasured
confounding effect needs to be very strong to completely account for this benefit. Second, we
didn't account for the effect of important supporting treatment such as oxygen and ventilator
use. Their availability and deployment may affect the estimated treatment effect. Third,
although the cohort size is 504, the patients from Tongji and Union Hospitals are not
necessarily the most representative samples of patients admitted into these hospitals. For
example, ICU patients in these two hospitals are not included. We have also excluded
surviving patients not yet discharged from WPH by March 29, 2020, and consequently, the
observed mortality rate among patients from WPH is substantially higher than that from
Tongji and Union Hospitals. These sampling biases may affect the interpretation and
generalizability of our findings. For example, the reported mortality rate doesn't represent the
absolute mortality rate in the patients admitted into relevant hospital. Furthermore, there are
only 33 patients who received both Arbidol and Oseltamivir in the entire cohort, which limits
the reliability of the estimated treatment benefit associated with the combination therapy. On
the other hand, despite the limited sample size and selective sampling, all identified risk
factors in the current study are consistent with other studies,[22,23] which indirectly supports our
findings on the treatment efficacy. The association between admission date and mortality can
also be explained by the availability of medical resources. Lastly, regarding the adverse
events, nausea was observed in a small group of patients who received Arbidol. Loss of
appetite was observed in patients who received Oseltamivir. Whereas Diarrhea, nausea,
vomiting, loss of appetite and decreased sleep quality were observed in patients who received
Lopinavir/Ritonavir. Due to the difficulty in accurate and complete documentation of all

adverse events during the pandemic, the study team did not summarize these data in this

report. Nevertheless, it is known that the severe adverse effects associated with the use of

Arbidol and Oseltamivir have been very rare.[21,24]

Arbidol is originated from Russia as a broad-spectrum antiviral drug and is now widely used

in Russia as an OTC drug and in China as a prescription drug. Although Arbidol was reported

to effectively shorten the duration of influenza and prevent the development of post-influenza

complications, reduce the re-infection risk based on multiple clinical trials conducted in

Russia and China,[25] due to lack of detailed information regarding these trials, WHO suggested

that the results should be interpreted with caution.[26] Consequently, Arbidol has not received

FDA approval in the United States and the use of Arbidol in other parts of the world has been

limited. However, while drafting this manuscript, we have found that eight clinical trials

(NCT04350684, NCT04286503, NCT04260594, NCT04273763, NCT04323345,

NCT04261907, NCT04306497, NCT04333589) in China, Iran and Egypt involving Arbidol

in treating COVID-19 patients were registered at www.clinicaltrial.gov.

In conclusion, our clinical and molecular biological findings suggest that Arbidol might be a

potentially effective treatment for COVID-19. Further clinical studies including RCTs are

warranted for statistical and clinical evaluation of its efficacy.

References

1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases

of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020

Feb 15;395(10223):507-513. doi: https://doi.org/10.1016/S0140-6736(20)30211-7. Epub

2020 Jan 30.

2. WHO Coronavirus disease (COVID-2019) situation reports.

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

(accessed May 22,2020)

3. Xie M, Chen Q. Insight into 2019 novel coronavirus - an updated interim review and

lessons from SARS-CoV and MERS-CoV. Int J Infect Dis. 2020 Apr 1. pii: S1201-

9712(20)30204-6. doi: https://doi.org/10.1016/j.ijid.2020.03.071. [Epub ahead of print]

4. Vanden EJ. COVID-19: A Brief Overview of the Discovery Clinical Trial.

Pharmaceuticals (Basel) 2020 Apr 10;13(4):E65. doi:

https://doi.org/10.3390/ph13040065.

5. Liu S, Lin H, Baine I, et al. Convalescent plasma treatment of severe COVID-19: A

matched control study. medRxiv preprint doi:

https://doi.org/10.1101/2020.05.20.20102236.

6. Mehra MR, Desai SS, Frank R, et al. Hydroxychloroquine or chloroquine with or without

a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet.

2020 May 22. doi: https://doi.org/10.1016/S0140-6736(20)31180-6

7. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in

Hospitalized Patients with Covid-19. N Engl J Med. 2020 May 7. doi:

https://doi.org/10.1056/NEJMoa2012410

8. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with

Severe Covid-19. N Engl J Med. 2020 Mar 18. doi:

https://doi.org/10.1056/NEJMoa2001282. [Epub ahead of print]

9. Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19: A

Randomized Clinical Trial. medRxiv preprint doi:

https://doi.org/10.1101/2020.03.17.20037432.

10. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A. Compassionate Use of

Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 April 10, at

NEJM.org. doi: https://doi.org/10.1056/NEJMoa2007016

11. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 —

Preliminary Report. N Engl J Med. 2020 May 22, doi:

https://doi.org/10.1056/NEJMoa2007764

12. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y. Remdesivir in Adults With Severe COVID-

19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial. Lancet. 2020

May 16;395(10236):1569–1578. doi: https://doi.org/10.1016/S0140-6736(20)31022-9.

Epub 2020 Apr 29.

13. Vankadari N, Wilce JA. Emerging COVID-19 coronavirus: glycan shield and structure

prediction of spike glycoprotein and its interaction with human CD26. Emerging

Microbes & Infections 9:1, pages 601–604. 2020

14. Li, Y, Zhang, Z, Yang, L, et al. The MERS-CoV receptor DPP4 as a candidate binding

target of the SARS-CoV-2 spike, ISCIENCE (2020), doi:

https://doi.org/10.1016/j.isci.2020.101160.

15. Vankadari N. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by

blocking the trimerization of viral spike glycoprotein? International Journal of

Antimicrobial Agents 105998 (2020) doi:

https://doi.org/10.1016/j.ijantimicag.2020.105998.

16. Image manipulation and analysis software: ImageJ freeware obtained

from http://imagej.nih.gov/ij/.

17. Xu R, Luo Y. Chambers C. 2012. Assessing the effect of vaccine on spontaneous abortion

using time- dependent covariates Cox models. Pharmacoepidemiology and drug

safety, 21(8), pp.844–850.

18. Wang X, Cao R, Zhang H, et al. The anti-influenza virus drug, arbidol is an efficient

inhibitor of SARS-CoV-2 in vitro. Cell Discov **6,** 28 (2020).

https://doi.org/10.1038/s41421-020-0169-8

19. Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W. Clinical Efficacy of Arbidol in Patients with

2019 Novel Coronavirus-Infected Pneumonia: A Retrospective Cohort Study (2020 Feb

12). Available at http://dx.doi.org/10.2139/ssrn.3542148

20. Proskurnina E, Izmailov D, Sozarukova M, Zhuravleva T, Leneva I, Poromov A.

Antioxidant Potential of Antiviral Drug Umifenovir. Molecules. 2020 Mar 30;25(7). pii:

E1577. doi: https://doi.org/10.3390/molecules25071577.

21. Blaising J, Polyak SJ, Pécheur EI. Arbidol as a broad-spectrum antiviral: An

update. Antiviral Res. 2014;107(1):84–94. doi:

https://doi.org/10.1016/j.antiviral.2014.04.006.

22. Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of

pneumonia patients coinfected with 2019 novel coronavirus and influenza virus

in Wuhan, China. J Med Virol. 2020 Mar 20. doi: https://doi.org/10.1002/jmv.25781.

[Epub ahead of print]

339
340
341
342   23. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–1062. doi: https://doi.org/10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.

23.   343   24. Uyeki T. Oseltamivir Treatment of Influenza in Children. Clin Infect

Dis. 2018;66(10):1501–1503.

25. Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ. Arbidol: a broad- spectrum antiviral

compound that blocks viral fusion. Curr Med Chem 2008;15(10):997–1005.

26. Who. WHO Guidelines for Pharmacological Management of Pandemic Influenza

A(H1N1) 2009 and other Influenza Viruses. WHO Guidel. Pharmacol. Manag. Pandemic

Influ. A(H1N1) 2009 other Influ. Viruses 1–32 (2010)

350
351

Table 1. Administered treatments for patients in three hospitals

	WPH n=373	Tongji n=100	Union n=31	Total n=504
Arbidol	141 (37.8%)	94 (94.0%)	22 (71.0%)	257 (51.0%)
Oseltamivir	46 (12.3%)	19 (19.0%)	1 (3.2%)	66 (13.1%)
Lopinavir/Ritonavir	245 (65.7%)	4 (4.0%)	10 (32.3%)	259 (51.4%)
Chloroquine	4 (1.1%)	0 (0.0%)	0 (0.0%)	4 (0.8%)
Hydroxycholoroquine	3 (0.8%)	0 (0.0%)	0 (0.0%)	3 (0.6%)
Favipiravir	4 (1.1%)	0 (0.0%)	0 (0.0%)	4 (0.8%)
Ganciclovir	28 (7.5%)	0 (0.0%)	2 (6.5%)	30 (6.0%)
Glucocorticoid	151 (40.5%)	73 (73.0%)	6 (19.4%)	230 (45.6%)
Immunoglobin	117 (31.4%)	25 (25.0%)	10 (32.3%)	152 (30.2%)
Albumin	71 (19.0%)	15 (15.0%)	2 (6.5%)	88 (17.5%)
Oxygen	318 (85.3%)	86 (86.0%)	23 (74.2%)	427 (84.7%)
Ventilation	43 (11.5%)	12 (12.0%)	0 (0%)	55 (10.9%)

Table 2. Distributions of Baseline Characteristics by Medication and Hospital

	WPH		Tongji		Union		Total	
Arbidol								
	Yes n=141	No n=232	Yes n=94	No n=6	Yes n=22	No n=9	Yes n=257	No n=247
Age (year)	61.3 (14.2)[1]	60.3 (15.0)	55.8 (14.6)	68.5 (9.6)	58.2 (17.3)	46.4 (15.3)	59.1 (14.8)	60.0 (15.1)
Female	72 (51.1%)	112 (48.3%)	41 (43.6%)	3 (50.0%)	12 (54.5%)	5 (55.6%)	125 (48.6%)	120 (48.6%)
Pre-existing conditions	90 (63.8%)	119 (51.3%)	33 (3 5.1%)	5 (83.3%)	11 (50.0%)	4 (44.4%)	134 (52.1%)	128 (51.8%)
SpO2 level (%)	93.6 (4.3)	91.7 (12.2)	93.9 (6.4)	81.3 (14.9)	95.8 (1.4)	96.8 (1.1)	93.9 (5.0)	91.6 (12.1)
Lesion Size (cm^2)	56.1 (43.4)	65.5 (48.4)	46.8 (31.2)	44.6 (19.7)	55.4 (38.9)	50.8 (42.6)	52.7 (39.1)	64.6 (47.9)
Admission Date[2] (day)	65.0 (13.4)	61.2 (22.0)	52.8 (1.4)	52.5 (1.4)	55.5 (7.3)	55.4 (5.5)	59.7 (11.7)	60.8 (21.4)
Oseltamivir								
	Yes n=46	No n=327	Yes n=19	No n=81	Yes n=1	No n=30	Yes n=66	No n=438
Age (year)	59.1 (13.5)	60.9 (14.8)	52.1 (12.8)	57.7 (14.9)	66.0	54.4 (17.5)	57.2 (13.6)	59.9 (15.1)
Female	24 (52.2%)	160 (48.9%)	9 (47.4%)	35 (43.2%)	1 (100%)	16 (53.3%)	34 (51.5%)	211 (48.2%)
Pre-existing Conditions	27 (58.7%)	182 (55.7%)	4 (21.1%)	34 (42.0%)	1 (100%)	14 (46.7%)	32 (48.5%)	230 (52.5%)
SpO2 level (%)	92.8 (6.4)	92.4 (10.4)	92.6 (7.7)	93.3 (7.7)	94.0	96.2 (1.3)	92.8 (6.7)	92.8 (9.6)
Lesion Size (cm^2)	67.8 (46.1)	60.3 (46.5)	47.1 (39.5)	46.7 (28.5)	43.0	54.5 (39.8)	61.5 (44.6)	57.2 (43.4)
Admission Date (day)	42.2 (10.1)	65.5 (18.5)	53.2 (1.2)	52.6 (1.4)	63.0	55.2 (6.7)	45.7 (10.0)	62.4 (16.9)
Lopinavir/Ritonavir								
	Yes n=245	No n=128	Yes n=4	No n=96	Yes n=10	No n=21	Yes n=259	No N=245
Age (year)	60.3 (13.4)	61.4 (16.9)	39.2 (16.3)	57.3 (14.2)	53.5 (12.4)	55.4 (19.5)	59.7 (13.6)	59.3 (16.2)
Female	122 (49.8%)	62 (48.4%)	2 (50.0%)	42 (43.8%)	6 (60.0%)	11 (52.4%)	130 (50.2%)	115 (46.9%)
Pre-existing Conditions	145 (59.2%)	64 (50.0%)	1 (25.0%)	37 (38.5%)	5 (50.0%)	10 (47.6%)	151 (58.3%)	111 (45.3%)
SpO2 level (%)	92.5 (8.5)	92.2 (12.4)	95.0 (4.1)	93.1 (7.8)	96.9 (0.9)	95.7 (1.4)	92.7 (8.3)	92.9 (10.2)
Lesion Size (cm^2)	61.6 (47.2)	61.0 (44.9)	22.6 (17.3)	48.0 (31.0)	44.4 (30.8)	59.0 (42.6)	60.2 (46.6)	55.1 (39.5)
Admission Date (day)	58.1 (15.4)	71.4 (22.7)	53.0 (1.6)	52.7 (1.4)	52.8 (5.0)	56.7 (7.2)	57.8 (15.0)	62.8 (18.8)

Figure 1: Diagram of cohort design and patient selection

Figure 2: Chest CT scan images before and after the antiviral treatment. The shaded areas circled by the yellow line were the lesion areas. Using ImageJ, we were able to quantify the sizes of the lesions in terms of squared centimeters. **(A)** A male patient in his 50s with no underlying diseases who have received Arbidol alone. **(B)** A male patient in his 50s with no underlying diseases who have received Oseltamivir + Lopinavir/Ritonavir, since no patient has received Oseltamivir alone. **(C)** A male patient in his 50s with no underlying diseases who have received Lopinavir/Ritonavir alone.

Figure 3: (A) The estimated OR and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir. **(B)** The estimated effect on relative change in lesion size and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir. An effect less than 1 suggests that more relative reduction in lesion size is associated with the medicine of interest. **(C)** The estimated OR and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir among 373 patients from WPH. **(D)** The estimated hazard ratio and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir based on the Cox regression analyses with time dependent covariates accounting for timings of medication use.

Model 1: adjusting for sex, pre-existing condition, log(age), log(SpO2), hospital, log(lesion size) and log(admission date); Model 2: adjusting for confounders in Model 1 and medication use (Arbidol, Oseltamivir, and Lopinavir/Ritonavir).

Figure 4: **(A)** Boxplot of the lesion absorption rate before and after the antiviral treatment, as shown in chest CT scan, compared among Arbidol, Oseltamivir, and Lopinavir/Ritonavir groups. In these boxplots we included CT lesion measures from all patients (deceased and discharged). **(B)** Cumulative mortality rate curves by medication use (Arbidol, Oseltamivir, and Lopinavir/Ritonavir). P-value of the log-rank tests are displayed and the shaded area shows the 95% confidence intervals

Figure 5: Surface and ribbon model showing the full length monomer **(A)** and homo-trimer **(B)** structure of SARS-CoV-2 spike glycoprotein. Position of S1 and S2 domains are labelled and bound Arbidol with high affinity at the center is shown in sticks. Each monomer of homo-trimer is shown in different colour.

Table 1. Administered treatments for patients in three hospitals

	WPH n=373	Tongji n=100	Union n=31	Total n=504
Arbidol	141 (37.8%)	94 (94.0%)	22 (71.0%)	257 (51.0%)
Oseltamivir	46 (12.3%)	19 (19.0%)	1 (3.2%)	66 (13.1%)
Lopinavir/Ritonavir	245 (65.7%)	4 (4.0%)	10 (32.3%)	259 (51.4%)
Chloroquine	4 (1.1%)	0 (0.0%)	0 (0.0%)	4 (0.8%)
Hydroxycholoroquine	3 (0.8%)	0 (0.0%)	0 (0.0%)	3 (0.6%)
Favipiravir	4 (1.1%)	0 (0.0%)	0 (0.0%)	4 (0.8%)
Ganciclovir	28 (7.5%)	0 (0.0%)	2 (6.5%)	30 (6.0%)
Glucocorticoid	151 (40.5%)	73 (73.0%)	6 (19.4%)	230 (45.6%)
Immunoglobin	117 (31.4%)	25 (25.0%)	10 (32.3%)	152 (30.2%)
Albumin	71 (19.0%)	15 (15.0%)	2 (6.5%)	88 (17.5%)
Oxygen	318 (85.3%)	86 (86.0%)	23 (74.2%)	427 (84.7%)
Ventilation	43 (11.5%)	12 (12.0%)	0 (0%)	55 (10.9%)

Table 2. Distributions of Baseline Characteristics by Medication and Hospital

	WPH		Tongji		Union		Total	
	Arbidol							
	Yes n=141	No n=232	Yes n=94	No n=6	Yes n=22	No n=9	Yes n=257	No n=247
Age (year)	61.3 (14.2)[1]	60.3 (15.0)	55.8 (14.6)	68.5 (9.6)	58.2 (17.3)	46.4 (15.3)	59.1 (14.8)	60.0 (15.1)
Female	72 (51.1%)	112 (48.3%)	41 (43.6%)	3 (50.0%)	12 (54.5%)	5 (55.6%)	125 (48.6%)	120 (48.6%)
Pre-existing conditions	90 (63.8%)	119 (51.3%)	33 (3 5.1%)	5 (83.3%)	11 (50.0%)	4 (44.4%)	134 (52.1%)	128 (51.8%)
SpO2 level (%)	93.6 (4.3)	91.7 (12.2)	93.9 (6.4)	81.3 (14.9)	95.8 (1.4)	96.8 (1.1)	93.9 (5.0)	91.6 (12.1)
Lesion Size (cm^2)	56.1 (43.4)	65.5 (48.4)	46.8 (31.2)	44.6 (19.7)	55.4 (38.9)	50.8 (42.6)	52.7 (39.1)	64.6 (47.9)
Admission Date[2] (day)	65.0 (13.4)	61.2 (22.0)	52.8 (1.4)	52.5 (1.4)	55.5 (7.3)	55.4 (5.5)	59.7 (11.7)	60.8 (21.4)
	Oseltamivir							
	Yes n=46	No n=327	Yes n=19	No n=81	Yes n=1	No n=30	Yes n=66	No n=438
Age (year)	59.1 (13.5)	60.9 (14.8)	52.1 (12.8)	57.7 (14.9)	66.0	54.4 (17.5)	57.2 (13.6)	59.9 (15.1)
Female	24 (52.2%)	160 (48.9%)	9 (47.4%)	35 (43.2%)	1 (100%)	16 (53.3%)	34 (51.5%)	211 (48.2%)
Pre-existing Conditions	27 (58.7%)	182 (55.7%)	4 (21.1%)	34 (42.0%)	1 (100%)	14 (46.7%)	32 (48.5%)	230 (52.5%)
SpO2 level (%)	92.8 (6.4)	92.4 (10.4)	92.6 (7.7)	93.3 (7.7)	94.0	96.2 (1.3)	92.8 (6.7)	92.8 (9.6)
Lesion Size (cm^2)	67.8 (46.1)	60.3 (46.5)	47.1 (39.5)	46.7 (28.5)	43.0	54.5 (39.8)	61.5 (44.6)	57.2 (43.4)
Admission Date (day)	42.2 (10.1)	65.5 (18.5)	53.2 (1.2)	52.6 (1.4)	63.0	55.2 (6.7)	45.7 (10.0)	62.4 (16.9)
	Lopinavir/Ritonavir							
	Yes n=245	No n=128	Yes n=4	No n=96	Yes n=10	No n=21	Yes n=259	No N=245
Age (year)	60.3 (13.4)	61.4 (16.9)	39.2 (16.3)	57.3 (14.2)	53.5 (12.4)	55.4 (19.5)	59.7 (13.6)	59.3 (16.2)
Female	122 (49.8%)	62 (48.4%)	2 (50.0%)	42 (43.8%)	6 (60.0%)	11 (52.4%)	130 (50.2%)	115 (46.9%)
Pre-existing Conditions	145 (59.2%)	64 (50.0%)	1 (25.0%)	37 (38.5%)	5 (50.0%)	10 (47.6%)	151 (58.3%)	111 (45.3%)
SpO2 level (%)	92.5 (8.5)	92.2 (12.4)	95.0 (4.1)	93.1 (7.8)	96.9 (0.9)	95.7 (1.4)	92.7 (8.3)	92.9 (10.2)
Lesion Size (cm^2)	61.6 (47.2)	61.0 (44.9)	22.6 (17.3)	48.0 (31.0)	44.4 (30.8)	59.0 (42.6)	60.2 (46.6)	55.1 (39.5)
Admission Date (day)	58.1 (15.4)	71.4 (22.7)	53.0 (1.6)	52.7 (1.4)	52.8 (5.0)	56.7 (7.2)	57.8 (15.0)	62.8 (18.8)

Figure 1: Diagram of cohort design and patient selection

Figure 2: Chest CT scan images before and after the antiviral treatment. The shaded areas circled by the yellow line were the lesion areas. Using ImageJ, we were able to quantify the sizes of the lesions in terms of squared centimeters. **(A)** A male patient in his 50s with no underlying diseases who have received Arbidol alone. **(B)** A male patient in his 50s with no underlying diseases who have received Oseltamivir + Lopinavir/Ritonavir, since no patient has received Oseltamivir alone. **(C)** A male patient in his 50s with no underlying diseases who have received Lopinavir/Ritonavir alone.

Figure 3: (A) The estimated OR and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir. **(B)** The estimated effect on relative change in lesion size and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir. An effect less than 1 suggests that more relative reduction in lesion size is associated with the medicine of interest. **(C)** The estimated OR and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir among 373 patients from WPH. **(D)** The estimated hazard ratio and associated 95% CI for Arbidol, Oseltamivir and Lopinavir/Ritonavir based on the Cox regression analyses with time dependent covariates accounting for timings of medication use.

Model 1: adjusting for sex, pre-existing condition, log(age), log(SpO2), hospital, log(lesion size) and log(admission date); Model 2: adjusting for confounders in Model 1 and medication use (Arbidol, Oseltamivir, and Lopinavir/Ritonavir).

Figure 4: **(A)** Boxplot of the lesion absorption rate before and after the antiviral treatment, as shown in chest CT scan, compared among Arbidol, Oseltamivir, and Lopinavir/Ritonavir groups. In these boxplots we included CT lesion measures from all patients (deceased and discharged). **(B)** Cumulative mortality rate curves by medication use (Arbidol, Oseltamivir, and Lopinavir/Ritonavir). P-value of the log-rank tests are displayed and the shaded area shows the 95% confidence intervals

Figure 5: Surface and ribbon model showing the full length monomer **(A)** and homo-trimer **(B)** structure of SARS-CoV-2 spike glycoprotein. Position of S1 and S2 domains are labelled and bound Arbidol with high affinity at the center is shown in sticks. Each monomer of homo-trimer is shown in different colour